Adreview

Active Ingredient(s): Iobenguane I 123
FDA Approved: * September 19, 2008
Pharm Company: * GE HEALTHCARE
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Adreview Overview

Iobenguane I 131, marketed under the trade name Azedra, has had a clinical trial as a treatment for malignant, recurrent or unresectable pheochromocytoma and paraganglioma, and the FDA approved it on July 30, 2018. The drug is developed by Progenics Pharmaceuticals.[10][11] References ^ Scarsbrook AF, Ganeshan A, Statham J, et al. (2007). "Anatomic and functional imaging of metastatic carcinoid tumors". Radiographics. 27 (2): 455–77. doi:10.1148/rg....

Read more Adreview Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Iobenguane

Recent Adreview Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Adreview: (1 result)

Sorted by National Drug Code

• 17156-235 Adreview 2 mci/Ml Intravenous Injection by Medi-physics Inc.

Other drugs which contain Iobenguane I 123 or a similar ingredient: (2 results)

• AZEDRA Iobenguane I 131
• IOBENGUANE I 123